State Street Corp Sells 40,056 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

State Street Corp lessened its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 2.9% during the third quarter, Holdings Channel.com reports. The fund owned 1,361,178 shares of the company’s stock after selling 40,056 shares during the period. State Street Corp’s holdings in Janux Therapeutics were worth $61,838,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics in the second quarter worth $29,000. Amalgamated Bank grew its stake in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new position in Janux Therapeutics in the 2nd quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics during the 2nd quarter worth approximately $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the transaction, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 42.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. bought 1,200,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was purchased at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This trade represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 192,032 shares of company stock valued at $9,512,515. 29.40% of the stock is currently owned by company insiders.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $55.13 on Thursday. Janux Therapeutics, Inc. has a one year low of $7.79 and a one year high of $71.71. The company has a market cap of $2.89 billion, a PE ratio of -47.12 and a beta of 3.29. The firm’s 50 day simple moving average is $53.55 and its 200 day simple moving average is $46.98.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The company’s revenue was down 82.6% compared to the same quarter last year. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JANX shares. Stifel Nicolaus lifted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. BTIG Research lifted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Finally, HC Wainwright increased their target price on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.